SCHEMBL22075944

SCHEMBL22075944

CCC(=O)N1CCCc2cc(OCC(=O)NCCOCCOCCC(=O)O)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.44
▸ ALDH1A1 P00352 7/20 0.44
▸ MAPK1 P28482 4/20 0.44
▸ TSHR P16473 2/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ LMNA P02545 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ TP53 P04637 3/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ PARP1 P09874 1/20 0.41
▸ PARP2 Q9UGN5 1/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ PDK1 Q15118 1/20 0.41
▸ PDK2 Q15119 1/20 0.41
▸ PDK3 Q15120 1/20 0.41
▸ PDK4 Q16654 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22075934 0.92 PARP1 (0.47) POLBALDH1A1TSHRLMNASMN1; SMN2
SCHEMBL22075954 0.92 PARP1 (0.47) POLBALDH1A1TSHRLMNASMN1; SMN2
SCHEMBL22075945 0.89 POLB (0.40) POLBALDH1A1MAPK1TSHRNPSR1
SCHEMBL22075920 0.84 PARP1 (0.45) POLBALDH1A1MAPK1TSHRLMNA
SCHEMBL29040445 0.84 HPGD (0.46) POLBALDH1A1TSHRLMNASMN1; SMN2
SCHEMBL30457557 0.84 HPGD (0.46) POLBALDH1A1TSHRLMNASMN1; SMN2
SCHEMBL22075928 0.82 PARP1 (0.43) ALDH1A1MAPK1TSHRNPSR1LMNA
SCHEMBL22075936 0.82 PARP1 (0.43) ALDH1A1MAPK1TSHRNPSR1LMNA
SCHEMBL22075950 0.82 PARP1 (0.46) ALDH1A1TSHRLMNASMN1; SMN2TP53
SCHEMBL22075949 0.81 TSHR (0.56) POLBALDH1A1MAPK1TSHRNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11691984-B2 Compounds and methods for DCAF-mediated protein degradation THE SCRIPPS RESEARCH INSTITUTE (US) 2023-07-04 — — US disclosed
US-11691984-B2 Compounds and methods for DCAF-mediated protein degradation THE SCRIPPS RESEARCH INSTITUTE (US) 2023-07-04 — — US disclosed
US-11691984-B2 Compounds and methods for DCAF-mediated protein degradation THE SCRIPPS RESEARCH INSTITUTE (US) 2023-07-04 — — US disclosed
EP-3864030-A1 COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION The Scripps Research Institute (US) 2021-08-18 — — EP disclosed
US-20200190105-A1 COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION THE SCRIPPS RESEARCH INSTITUTE 2020-06-18 — — US disclosed
US-20200190105-A1 COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION THE SCRIPPS RESEARCH INSTITUTE 2020-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190105-A1 COMPOUNDS AND METHODS FOR DCAF-MEDIATED PROTEIN DEGRADATION DCAF1, CUL4A, DCAF15 POLB 2891/4885ALDH1A1 2600/4885MAPK1 3651/4885
US-11691984-B2 Compounds and methods for DCAF-mediated protein degradation DCAF1, CUL4A, DCAF15 POLB 2891/4885ALDH1A1 2600/4885MAPK1 3651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback